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INTRODUCTION
Thyroid-associated ophthalmopathy (TAO) is an ophthalmic 
disease that frequently accompanies Graves’ disease (GD). In 
general, 25–50% of patients with GD are diagnosed with clini-
cally significant TAO.1 TAO follows a characteristic clinical 
course, called Rundle’s curve,2 in which TAO worsens during an 
initial phase, peaks at maximum severity, improves, and reach-
es a static plateau, with the activity curve preceding the severity 
curve by a few months. Throughout the course of the disease, 
patients present with characteristic symptoms of lid swelling, 
chemosis, proptosis, lid retraction, diplopia due to limited oc-
ular movement, and deep orbital pain, each with variable se-
verity. While most patients experience remission through ces-
sation of the active inflammatory stage by medical interferences, 
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Purpose: This study was conducted to identify and to functionally characterize genetic variants in ST3GAL5 and ST8SIA1 in Kore-
an patients with thyroid-associated ophthalmopathy (TAO). 
Materials and Methods: Genetic analyses were conducted using DNA samples from TAO patients (n=50) and healthy subjects 
(n=48) to identify TAO-specific genetic variants of ST3GAL5 or ST8SIA1. The effect of each genetic variant on the transcription or 
expression of these genes was examined. Additionally, correlations between functional haplotypes of ST3GAL5 or ST8SIA1 and 
clinical characteristics of the patients were investigated.
Results: Six promoter variants and one nonsynonymous variant of ST3GAL5 were identified, and four major promoter haplotypes 
were assembled. Additionally, three promoter variants and two major haplotypes of ST8SIA1 were identified. All ST3GAL5 and 
ST8SIA1 variants identified in TAO patients were also found in healthy controls. Promoter activity was significantly decreased in 
three promoter haplotypes of ST3GAL5 and increased in one promoter haplotype of ST8SIA1. Transcription factors activating pro-
tein-1, NKX3.1, and specificity protein 1 were revealed as having roles in transcriptional regulation of these haplotypes. The non-
synonymous variant of ST3GAL5, H104R, did not alter the expression of ST3GAL5. While no differences in clinical characteristics 
were detected in patients possessing the functional promoter haplotypes of ST3GAL5, exophthalmic values were significantly 
lower in patients with the ST8SIA1 haplotype, which showed a significant increase in promoter activity.
Conclusion: These results from genotype-phenotype analysis might suggest a possible link between the ST8SIA1 functional pro-
moter haplotype and the clinical severity of TAO. However, further studies with larger sample sizes are warranted.
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such as administration of corticosteroids, without a need for ad-
ditional treatment, a considerable number of patients require 
surgical interventions, such as orbital decompression for pro-
ptosis, strabismus surgery, and levator recession for lid retrac-
tion. Moreover, approximately 3−5% of patients with TAO suf-
fer from severe disease with intense inflammation, resulting in 
devastating complications, such as sight-threatening corneal 
ulceration and compressive optic neuropathy.3
Smoking is widely accepted as a critical environmental risk 
factor that affects the severity of TAO.4 Smokers with TAO are 
more likely than nonsmokers to develop severe disease and 
less likely to respond well to immunosuppressive therapies,5 
which provides concrete evidence for discouraging smoking 
in TAO patients. With the development of technologies for ge-
netic study, an increasing number of researchers have investi-
gated the association between genetic variants and suscepti-
bility to or severity of numerous diseases, including TAO. Poly-
morphisms in several genes including those encoding inter-
leukin (IL)-1β, IL-12B, toll-like receptors, poly (ADP-ribose) po-
lymerase-1, and nuclear factor-kappa B (NF-κB) are significantly 
associated with TAO susceptibility.6-9
ST3GAL5 (lactosylceramide alpha-2,3-sialyltransferase) 
and ST8SIA1 (ST8 alpha-N-acetyl-neuraminide alpha-2,8-sial-
yltransferase 1) are members of the sialyltransferase family and 
are involved in the production of gangliosides. By enzymatic 
activity that transfers sialic acid to nascent oligosaccharide, 
ST3GAL5 converts lactosylceramide into monosialodihexosyl-
ganglioside 3 (GM3), and ST8SIA1 converts GM3 to disialogan-
glioside 3 (GD3), which is a precursor of trisialoganglioside 1b 
(GT1b).10 Previously, we observed that mRNA levels of ST3GAL5 
and ST8SIA1 increased in orbital fat tissues obtained from 
TAO patients, compared with those from healthy controls.11 In 
addition, GT1b induced an increase in hyaluronic acid (HA) 
in orbital fibroblasts.11 HA is a key molecule in determining TAO 
severity, based on its hydrophilic characteristics and its ability 
to induce tissue edema by accumulation in orbital connective 
tissue and extraocular muscles.12 Taken together, one can pos-
tulate a possible impact of ST3GAL5 or ST8SIA1 genetic vari-
ants and the resulting alteration of their activity on suscepti-
bility to and/or severity of TAO. However, to the best of our kn-
owledge, a genetic variant of ST3GAL5 or ST8SIA1 has not yet 
been studied in TAO patients.
In the present study, we conducted genetic analyses using 
DNA samples from 50 TAO patients to identify the TAO-spe-
cific genetic variants of ST3GAL5 or ST8SIA1. In addition, we 
examined the effect of each genetic variant on the transcription 
or expression of these genes. Finally, we investigated correla-
tions between functional haplotypes of ST3GAL5 and ST8SIA1 
and the clinical characteristics of the patients.
MATERIALS AND METHODS
Subjects
This study was approved by the Institutional Review Board of 
Ajou Medical Center, Suwon, Korea and the Institutional Re-
view Board of Severance Hospital in the Yonsei University 
Health System, Seoul, Korea. All experiments and analyses were 
performed in accordance with relevant guidelines and regula-
tions of the Institutional Review Boards of Ajou Medical Center 
and the Yonsei University Health System. DNA samples were 
obtained from peripheral blood upon obtaining written in-
formed consent from 50 Korean patients with TAO (8 males 
and 42 females); those diagnosed with TAO had at least a 12- 
month follow-up period prior to the enrollment in this study. 
Mean age was 42.1±14.0, and the follow-up period ranged from 
12 to 78 (28.6±19.4) months. During this period, the patient as-
sessments were performed by a single oculoplastic specialist 
in each hospital. According to the No signs or symptoms, Only 
signs without symptoms, Soft tissue involvement, Proptosis, 
Extraocular muscle involvement, Corneal involvement, Sight 
loss (NOSPECS) classification,13 patients with dysthyroid dis-
ease, showing symptoms in addition to soft tissue involve-
ment, were diagnosed with TAO. Clinical activity was mea-
sured by the clinical activity score (CAS), which included 
clinical symptoms and signs of TAO (Table 1).14 For the exoph-
thalmos measurements, the same type of Hertel exophthal-
mometer was used at both hospitals, which has been shown 
to be a reliable method for measuring ocular protrusion, show-
ing good intra-observer agreement and clinically acceptable 
inter-observer agreement without significant variations.15 Clini-
cal data were collected by reviewing medical records. For the 
control group, DNA samples from 48 healthy Koreans were ob-
tained from DNA Link, Inc. (Seoul, Korea), a genomic service 
provider established in March 2000 and based in Korea focus-
ing on research and development in the field of bio-industry 
and genomic analysis industry.
Genetic analysis
Genetic variants of ST3GAL5 and ST8SIA1 were identified by 
direct sequencing of the promoter (-2295 through +417, and 
-2539 through +176, from translation start site, respectively) 
and whole exons. Haplotype assembly was conducted using 
Haploview software, version 4.3 (Broad Institute, Cambridge, 
MA, USA). The GenBank mRNA sequences (accession num-
Table 1. Components of the Clinical Activity Score
Spontaneous retrobulbar pain
Pain on attempted upward or downward gaze
Redness of eyelids
Redness of conjunctiva
Swelling of caruncle or plica
Swelling of eyelids
Swelling of conjunctiva (chemosis)
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bers NM_003896 and NM_003034) were used as reference se-
quences for ST3GAL5 and ST8SIA1, respectively, in this study.
Construction of vectors
To construct the ST3GAL5 reporter plasmid, 2040-bp regions 
of the gene were amplified and inserted into the pGL4.11b[luc2] 
vector (Promega Corporation, Fitchburg, WI, USA). The ST8SIA1 
reporter plasmid was constructed by amplifying and inserting 
1977-bp regions into the pGL4.11[luc2P] vector (Promega Cor-
poration). To evaluate the effect of variants in the coding region 
on ST3GAL5 expression, we constructed the ST3GAL5 refer-
ence plasmid; ST3GAL5 cDNA was purchased (GE Healthcare 
Bio-Sciences, Pittsburgh, PA, USA) and subcloned into the 
pcDNA3.1(+) vector (Life Technologies Corporation, Carlsbad, 
CA, USA). Haplotypes or variants in the promoter region and 
a nonsynonymous variant were generated using a QuikChange2® 
II site-directed mutagenesis kit (Agilent Technologies, Santa 
Clara, CA, USA). All DNA sequences were confirmed by direct 
sequencing. Supplementary Table 1 (only online) lists the prim-
ers used in this study.
Measurement of promoter activity
Previously, we measured luciferase activities of several genes 
after transfection of reporter vectors into different cell line, such 
as HCT-116, HEK-293, HeLa, ACHN, and HepG2.16-18 Then we 
observed that, regardless of the type of overexpressed gene, 
HCT-116 (human colon carcinoma) cells showed the highest 
promoter activity. Therefore, after transfection of ST3GAL5 
and ST8SIA1 reporter plasmids into HCT-116 cells using Lipo-
fectamine LTX and Plus reagents (Life Technologies Corpora-
tion), the luciferase activity of each vector was measured using 
a Dual-Luciferase2® Reporter Assay System (Promega Corpora-
tion), according to the manufacturer’s protocol. A Renilla vector 
was used to equalize the amounts of each transfected plasmid.
Prediction of transcription factors and electrophoretic 
mobility shift assay
TFSearch (version 3.1, Real-World Company Partnership, To-
kyo, Japan), MatInspector (Genomatix Software GmbH, Mu-
nich, Germany), and ConSite (http://consite.genereg.net/cgi-
bin/consite) were used to predict transcription factors that 
bind to the ST3GAL5 or ST8SIA1 promoter regions with bind-
ing affinities that would be affected by their variants. For elec-
trophoretic mobility shift assay (EMSA), nuclear proteins from 
HCT-116 cells were incubated with 32P-labeled oligonucle-
otides for 30 min at room temperature. Protein-DNA mixtures 
were then separated by 6% non-denaturing polyacrylamide 
gel electrophoresis. For the competition assay, 50- or 100-fold 
molar excess of unlabeled consensus or core sequence-mu-
tated oligonucleotides was used. In the EMSAs for activating 
protein-1 (AP-1) and specificity protein 1 (SP1), supershift as-
says were performed using 4 µg of antibodies against phospho-
c-Jun (9164, Cell Signaling Technology, Danvers, MA, USA) 
and SP1 (sc-420X, Santa Cruz Biotechnology, CA, USA), re-
spectively. The oligonucleotides used in the EMSA are listed 
in Supplementary Table 2 (only online).
Measurement of protein expression
The ST3GAL5 reference or variant plasmids were transfected 
into HCT-116 cells. Forty-eight hours after transfection, cell ly-
sates were obtained, and immunoblotting was carried out. A 
rabbit anti-ST3GAL5 antibody (Abcam, Cambridge, UK) was 
used as the primary antibody, and β-actin was used as an in-
ternal standard.
Statistical analysis
Data analysis was conducted using IBM SPSS Statistics soft-
ware, version 21 (IBM Corp., Armonk, NY, USA). Luciferase ac-
tivity or protein expression was compared between the ST-
3GAL5 or ST8SIA1 references and their variants by one-way 
analysis of variance, followed by a Dunnett’s two-tailed test. 
To examine the effect of ST3GAL5 or ST8SIA1 functional hap-
lotypes on the clinical course of TAO, we used the Mann−Whit-
ney nonparametric test. Data are represented as mean values± 
standard deviation (SD). p-values of less than 0.05 were con-
sidered statistically significant.
RESULTS
Genetic variations of ST3GAL5 and ST8SIA1
Sequencing of genomic DNA samples from 50 TAO patients 
revealed six genetic variants in the promoter region of ST3GAL5 
and one nonsynonymous variant. In the case of ST8SIA1, three 
promoter variants were identified, while there was no non-
synonymous variant of this gene in our population. Table 2 
shows the frequencies of genetic variants of ST3GAL5 and 
ST8SIA1. However, we found that those variants were not TAO-
specific: all variants identified in TAO patients were observed 
in the 48 healthy controls, and the frequency of each variant 
was comparable between the two groups (Supplementary Ta-
ble 3, only online). After haplotype construction with the gen-
otype data, we observed four and two common (frequency 
≥5%) promoter haplotypes in ST3GAL5 and ST8SIA1, respec-
tively (Tables 3 and 4). Of those haplotypes, haplotype 2 (H2) 
of ST3GAL5 and haplotype 1 (H1) of ST8SIA1 were used as 
reference haplotypes in the present study, based on accession 
numbers NM_003896 and NM_003034 in the National Center 
for Biotechnology Information database of single-nucleotide 
polymorphisms (SNPs).
Effect of genetic variants on the promoter activities of 
ST3GAL5 and ST8SIA1
To the best of our knowledge, no studies have investigated the 
effect of ST3GAL5 or ST8SIA1 promoter variants on the tran-
scription of these genes. Here, we constructed vectors con-
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taining ST3GAL5 and ST8SIA1 promoter variants or haplo-
types and measured the luciferase activity of each vector. Three 
ST3GAL5 haplotypes exhibited a significant decrease in pro-
moter activity, compared with the reference (H2) (Fig. 1A); pro-
moter activities of H1, H3, and H4 were decreased by 13.45, 
39.04, and 17.32%, respectively. Two variants, g.-1468C>G and 
g.-1051G>C, present in H1, H3, and H4, exhibited significantly 
decreased promoter activities, compared with the reference, 
by 33.53 and 39.0%, respectively (Fig. 1B). In the case of ST8SIA1, 
H2 showed increased promoter activity, compared with the 
reference (H1) (Fig. 1C), by 102.30%. Two variants, g.-2196A>C 
and g.-1984T>C, in H2 were involved in an increase in activity 
of H2; they showed increased promoter activities, compared 
with the reference, by 40.37 and 70.36%, respectively (Fig. 1D).
Transcriptional regulation of ST3GAL5 and ST8SIA1 
promoter variants
We then conducted transcription factor binding site (TFBS) 
analyses to predict which transcription factors would bind to 
the ST3GAL5 or ST8SIA1 promoter regions and were involved 
in the transcriptional regulation of genetic variants. TFSearch 
and MatInspector predicted that the transcription factors 
AP-1 and v-Myb would bind in the g.-1051G>C and g.-1468C>G 
variant regions, respectively, and that the binding affinities of 
these transcription factors would be affected by each genetic 
Table 2. Frequency of ST3GAL5 or ST8SIA1 Genetic Variations in Thyroid-Associated Ophthalmopathy Patients 
rs no. Variant Minor allele Frequency rs no. Variant Minor allele Frequency
ST3GAL5 promoter
rs12714154 g.-1930A>G G 0.510 rs4832216 g.-1051G>C G 0.260
rs11674537 g.-1626G>A A 0.130 rs4832216 g.-141T>C T 0.260
rs11674561 g.-1468C>G G 0.130 rs28364795 g.-140C>A A 0.510
ST3GAL5 coding
rs3731824 c.311A>G (H104R) G 0.350
ST8SIA1 promoter
rs3809201 g.-2196A>C C 0.099 - g.-681G>C C 0.010
rs3809202 g.-1984T>C C 0.099
Table 3. Frequency of ST3GAL5 Promoter Haplotypes 
ID g.-1930A>G g.-1626G>A g.-1468C>G g.-1051G>C g.-141T>C g.-140C>A Frequency
H1 G G C C C A 0.510
H2 A G C G T C 0.260
H3 A A G C C C 0.130
H4 A G C C C C 0.100
The single-nucleotide polymorphisms were marked in bold-faced letters. The minor alleles were marked in letters with underlines.
Table 4. Frequency of ST8SIA1 Promoter Haplotypes 
ID g.-2196A>C g.-1984T>C g.-681G>C Frequency
H1 A T G 0.900
H2 C C G 0.100
The single-nucleotide polymorphisms were marked in bold-faced letters. The 
minor alleles were marked in letters with underlines.
variant. To validate the TFBS, we performed EMSAs. To exam-
ine AP-1 binding to the g.-1051G>C variant, nuclear extracts 
were incubated with 32P-labelled oligonucleotides (lanes 1−3, 
AP-1 consensus; lanes 4−6, g.-1051G reference; lanes 7−9, g.-
1051C variant) (Fig. 2A), and the reaction mixtures were sepa-
rated by electrophoresis. We observed that reference or variant 
oligonucleotides formed DNA-protein complexes at the same 
position as the AP-1 consensus oligonucleotide-protein com-
plex; however, the intensity of the variant oligonucleotides-
protein complex increased by 12%, compared with the refer-
ence (lanes 1, 4, and 7) (Fig. 2A). The competition assay using 
a 100-fold molar excess of unlabeled AP-1 consensus oligonu-
cleotides revealed that the DNA-protein complexes contained 
AP-1 (lanes 2, 5, and 8) (Fig. 2A). To validate the competition 
assay, we performed a supershift assay using an antibody 
against AP-1 (lanes 3, 6, and 9) (Fig. 2A). The DNA-protein com-
plexes supershifted with the antibody, indicating that these 
bands contained complexes of DNA with AP-1. To determine 
whether v-Myb could bind to the g.-1468C>G variant region, 
we performed a gel shift assay and confirmed that v-Myb bound 
to the ST3GAL5 g.-1468C>G promoter region. However, the 
binding affinity for v-Myb was comparable between the refer-
ence and variant (Supplementary Fig. 1, only online). In the 
case of ST8SIA1, two transcription factors, NKX3.1 and SP1, 
were predicted to bind in the g.-2196A>C and g.-1984T>C> 
variant regions of ST8SIA1, respectively. We observed that 
NKX3.1 had a higher affinity to the reference g.-2196A than 
the variant g.-2196C (lanes 4 and 7) (Fig. 2B) through a com-
petition assay using a 100-fold molar excess of unlabeled 
NKX3.1 consensus (lanes 5 and 8) (Fig. 2B) or core sequence-
mutated oligonucleotides (lanes 6 and 9) (Fig. 2B). Finally, in 
the competition assay using a 100-fold molar excess of unla-
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beled SP1 consensus oligonucleotides (lanes 5 and 8) (Fig. 
2C), SP1 bound to the promoter region near the g.-1984T>C 
variant, and the binding affinity was increased by the pres-
ence of this variant (lanes 4 and 7) (Fig. 2C). The supershift us-
ing the antibody against SP1 confirmed that these DNA-pro-
tein complexes contained SP1 (lanes 3, 6, and 9) (Fig. 2C).
Effect of ST3GAL5 nonsynonymous variant H104R on 
protein expression
In general, nonsynonymous variants resulting in amino acid 
changes frequently alter the expression or function of genes. In 
the present study, we identified one nonsynonymous variant 
of ST3GAL5, H104R. To date, the effect of this variant on ST-
3GAL5 expression is not known. Therefore, we constructed a 
vector containing ST3GAL5 reference sequences or the H104R 
variant, and used immunoblotting to determine whether H104R 
affects ST3GAL5 expression. We observed that ST3GAL5 ex-
pression with the H104R variant was similar to that with the 
reference (Fig. 3).
Effects of functional haplotypes of ST3GAL5 and 
ST8SIA1 on the clinical course of TAO patients
Although genetic variants or haplotypes of ST3GAL5 and 
ST8SIA1 identified in this study are not TAO-specific, we in-
vestigated whether functional haplotypes of these genes affect 
the clinical severity thereof during patient follow-up. To ex-
amine this, the demographic and clinical characteristics of 
patients, including CAS, exophthalmic value, number of cyclic 
treatments with steroids, and total amount of steroid used, 
were collected and compared according to the ST3GAL5 or 
ST8SIA1 functional promoter haplotypes. Of the 50 patients, 
15 were excluded from these comparisons owing to missing 
data. The ST3GAL5 functional promoter haplotypes H1, H3, 
and H4 did not affect the clinical characteristics of TAO pa-
tients (Table 5). However, we observed that patients with 
ST8SIA1 H2 had a lower exophthalmic value at the first visit, 
compared with patients without H2 (19.11±1.58 mm in the 
variant vs. 20.99±3.52 mm in the control groups, p=0.007). In 
addition, the peak exophthalmic value of patients with H2 
during the follow-up period was less than that in those with-
out H2 (19.75±2.02 mm in the variant vs. 22.00±3.42 mm in 
the control groups, p=0.003) (Table 6). Other parameters, in-
cluding CAS at the first visit, peak CAS during the follow-up 
period, total amount of steroid used, and number of steroid 
pulse cycles, were comparable between the two groups. Demo-
graphic characteristics, including age, gender, length of fol-
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Fig. 1. Effect of genetic variants on the promoter activity of ST3GAL5 or ST8SIA1. Luciferase activities were measured 30 hours after transfection of 
the reporter vectors containing ST3GAL5  (A and B) or ST8SIA1 (C and D) haplotypes (A and C) or variants (B and D) into HCT-116 cells. The luciferase 
activity of each construct was compared with that of the reference (REF). The data (mean±SD) were obtained from triplicate wells. *p<0.01, †p<0.001.
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low-up period, family history, smoking status, and comorbidi-
ties (hypertension and diabetes), exhibited no significant dif-
ference between the groups (data not shown).
DISCUSSION
ST3GAL5 is ubiquitously distributed throughout the body and 
is particularly abundant in the central nervous system.19,20 To 
date, a few researchers have investigated the association be-
tween genetic variants of ST3GAL5 and human disease. Ani-
mal and clinical studies have shown that loss or decreased 
function of ST3GAL5 is associated with enhanced insulin sen-
sitivity, early-onset epilepsy, and complete hearing loss.21-24 
ST8SIA1 is mainly expressed in the brain, kidney, thymus, and 
testes.19 Previous study reported that several SNPs of ST8SIA1 
were significantly associated with susceptibility to multiple 
sclerosis, while another study reported that there was no signif-
icant association between multiple sclerosis and these SNPs 
in their study populations.25,26
Here, we investigated the functional effect of genetic vari-
ants in ST3GAL5 and ST8SIA1 using in vitro molecular assays. 
Three ST3GAL5 promoter haplotypes, H1, H3, and H4, exhib-
ited a significant decrease in promoter activity: H3 had the 
most significant decrease (45%). Decreased activities of these 
haplotypes were due to two genetic variants, g.-1468C>G and 
Fig. 2. Effect of genetic variants on the binding of the transcription factors to ST3GAL5 (A) or ST8SIA1 (B and C) promoters. (A) 32P-labelled oligonucle-
otides (lanes 1-3, AP-1 consensus; lanes 4-6, g.-1051G reference; lanes 7-9, g.-1051C variant) were incubated with nuclear protein extracts (25 μg) ob-
tained from HCT-116 cells. Competition assay was performed using 100-fold molar excess of unlabeled AP-1 consensus oligonucleotides (lanes 2, 5, 
and 8). Supershift assays were performed with an antibody against phosphorylated c-Jun (lanes 3, 6, and 9). (B) 32P-labelled oligonucleotides (lanes 
1-3, NKX3.1 consensus; lanes 4-6, g.-2196A reference; lanes 7-9, g.-2196C variant) were incubated with nuclear protein extracts (25 μg) obtained from 
HCT-116 cells. Competition assay was performed using 100-fold molar excess of unlabeled NKX3.1 consensus (Ref, lanes 2, 5, and 8) or core se-
quence-mutated (Mut, lanes 3, 6, and 9) oligonucleotides. (C) 32P-labelled oligonucleotides (lanes 1-3, SP1 consensus; lanes 4-6, g.-1984T reference; 
lanes 7-9, g.-1984C variant) were incubated with nuclear protein extracts (25 μg) obtained from HCT-116 cells. Competition assay was performed us-
ing 100-fold molar excess of unlabeled SP1 consensus oligonucleotides (lanes 2, 5, and 8). Supershift assays were performed with an antibody 
against SP1 (lanes 3, 6, and 9). The arrows indicate the position of the DNA-protein complex.
Label AP-1 ST3GAL5, g.-1051G ST3GAL5, g.-1051C
Competitor
Antibody
- + - - + - - + -
- - + - - + - - +
1 2 3 4 5 6 7 8 9
Label SP1 ST8SIA1, g.-1984T ST8SIA1, g.-1984C
Competitor
Antibody
- + - - + - - + -
- - + - - + - - +
1 2 3 4 5 6 7 8 9
Label NKX3.1 ST8SIA1, g.-2196A ST8SIA1, g.-2196C
Competitor - Ref Mut - Ref Mut - Ref Mut
1          2            3           4          5             6          7          8            9
A
C
B
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g.-1051G>C, present in H1, H3, and H4. Previous studies have 
reported that a number of transcription factors, AP-4, myeloid 
zinc finger-1, SP1, and cAMP-responsive element binding pro-
tein (CREB), regulate the transcription of ST3GAL5.27-29 Among 
them, Chung, et al.29 reported that CREB is activated by pro-
tein kinase C and the extracellular regulated kinase signal 
transduction pathway, and induces ST3GAL5 expression. Th-
rough TFBS analysis and EMSA, we found that a transcription 
factor, AP-1, regulates ST3GAL5 transcription. AP-1 is a strong 
oncogene and is expressed in a variety of tumors.30 Previous 
studies have reported that AP-1 acts bifunctionally as an induc-
er or repressor for the transcription of various genes.16,31-34 In 
this study, we observed that the ST3GAL5 promoter contains 
the sequence, CGTGAGA, similar to a/gc/gTGACT, the consen-
sus sequence recognized by AP-1. The variant g.-1051G>C re-
sults in the sequence, CGTGACA, which more closely resem-
Table 5. Comparison of Clinical Characteristics According to ST3GAL5 Haplotypes
Parameter With H1, H3, and H4 (n=16) Without H1, H3, and H4 (n=19) p value
Exophthalmos (mm)
At first visit 21.23±2.84 20.09±3.60 0.192
Peak value* 22.08±2.62 21.11±3.76 0.249
CAS 
At first visit 2.66±1.87 2.08±1.99 0.199
Peak value* 2.72±1.82 2.71±1.74 0.901
Corticosteroid treatment
Total used amounts (mg)* 2368.33±2250.12 3150.63±2481.90 0.310
Number of pulse cycle* 0.93±0.96 1.61±1.34 0.053
CAS, clinical activity score.
*During total follow-up period.
Table 6. Comparison of Clinical Characteristics According to the ST8SIA1 Haplotype
Parameter With H2 (n=7) Without H2 (n=28) p value
Exophthalmos (mm)
At first visit 19.11±1.58 20.99±3.52 0.007
Peak value* 19.75±2.02 22.00±3.42 0.003
CAS 
At first visit 1.86±1.75 2.46±1.98 0.332
Peak value* 2.29±1.59 2.82±1.80 0.333
Corticosteroid treatment
Total used amounts (mg)* 2627.50±1012.67 2787.96±2518.96 0.892
Number of pulse cycle* 1.33±0.52 1.30±1.33 0.519
CAS, clinical activity score.
*During total follow-up period.
Fig. 3. Effect of a nonsynonymous variant, H104R, on ST3GAL5 expression. Immunoblotting assays were performed using cell lysates obtained 48 
hours after the transfection of empty vector (EV, pcDNA3.1), ST3GAL5 reference (REF), or variant plasmids into HCT-116 cells. The data (mean±SD) 
were obtained from three representative experiments. β-actin was used as an internal control. 
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bles the AP-1 consensus sequence. Based on this observation, 
we predicted that AP-1 would preferentially bind to the variant 
DNA sequence over the reference; this prediction was indeed 
confirmed by EMSA. We further examined the effect of AP-1 
on the ST3GAL5 promoter activity by using siRNA to knock-
down c-Jun, one of components of AP-1. As a result, we ob-
served that a significant increase in promoter activity of the ref-
erence (H2) and g.-1051G>C reporter constructs in the presence 
of c-Jun siRNA, compared with the promoter activities with the 
negative control siRNA, by 50.55 and 76.66%, respectively (Sup-
plementary Fig. 2, only online). This result suggests that AP-1 
works as a repressor of ST3GAL5 transcription. Regarding 
ST8SIA1, Kang, et al.35 reported that the ST8SIA1 promoter con-
tains binding sites for transcriptional factors, including C-Ets-1, 
CREB, AP-1, and NF-κB, which play an important role in the 
induction of ST8SIA1 expression in Fas-activated Jurkat T 
cells. In the present study, H2, a haplotype of ST8SIA1, showed 
a significant increase in promoter activity, and two transcrip-
tional factors, NKX3.1 and SP1, were identified as playing a 
role in the regulation of ST8SIA1 activity. NKX3.1 is known as 
a tumor suppressor gene of prostatic cancer, and a functional 
variant in this gene is associated with increased prostate can-
cer risk.36,37 SP1 is ubiquitously expressed and works as a house-
keeping transcription factor.38 For example, it plays a role in 
the insulin regulation of gene expression.39 Previous study re-
ported that the promoter of mouse lysosomal sialidase, which 
plays a role in the catabolism of gangliosides, is responsive to 
SP1.40
Previously, we observed that mRNA levels of ST3GAL5 and 
ST8SIA1 increased in orbital fat tissues obtained from TAO pa-
tients, compared with healthy controls.11 In the present study, 
we could not find TAO-specific ST3GAL5 or ST8SIA1 variants: 
all identified genetic variants were found in the healthy sub-
jects. Multifactorial mechanisms have been suggested to be 
involved in the pathogenesis of TAO.4 Taken together with the 
clinical phenomenon that not all GD patients present with 
TAO, future studies including patients with GD who have no 
sign of TAO are needed to be performed. In terms of the severi-
ty of this disease, we observed that patients with the ST8SIA1 
haplotype H2, which showed an increase of promoter activity, 
showed less severe exophthalmos, compared with patients 
without H2. Moreover, although it was not statistically signifi-
cant, TAO patients without ST3GAL5 haplotypes H1, H3, and 
H4 that showed an increase of promoter activity also showed 
a tendency to experience less severe exophthalmos, compared 
with the other group. In patients with TAO, proptosis develops 
as a result of the increased volume of orbital tissues, such as 
extraocular muscle and orbital fat, which is caused by the 
edematous change. Deposition of HA is one of the pathologic 
changes in the orbital tissue of patients with TAO and is be-
lieved to be one of the causes of tissue edema from the hydro-
philic characteristic of HA. Taken together with previous find-
ings showing that GT1b increase HA11 and that HA induces 
cyclooxygenase-2 in orbital fibroblasts,41 the present results 
contradict the expectation that patients possessing haplotypes 
of ST3GAL5 or ST8SIA1 with increased promoter activity 
would show more severe clinical phenotypes. One possible ex-
planation for this discrepancy might be the involvement of oth-
er mechanisms that modulate the synthesis and/or secretion 
of GT1b and/or HA in orbital fibroblasts, as illustrated by the 
divergent effects of IL-4 and interferon-γ on IL-1β-induced HA 
and prostaglandin E2 production.42 In addition, in vivo, orbit-
al fibroblasts in TAO receive signals from a combination of 
various mediators, and possibly interfere with each other’s in-
dividual biological effects, so that the net biological effect of 
orbital fibroblast activating factors in the pathophysiology of 
TAO is complex.
Limitations of this study include the insufficient sample size 
used in the analysis of the clinical data to achieve strong sta-
tistical power, and the lack of actual observations of promoter 
activity depending on the presence of genetic variants in the 
orbital tissues of the corresponding patients. Therefore, to val-
idate the relevance of the functional characteristics of the iden-
tified genetic variants to the clinical characteristics of TAO pa-
tients, more association studies with a large number of samples, 
including the orbital tissues, should be performed. Another 
limitation is that we could not examine the effect of the differ-
ences in the promoter activities of ST3GAL5 or ST8SIA1 de-
pending on its variants on the actual expression level and/or 
activity of these enzymes. To the best of our knowledge, no 
study has been reported in which the activity of ST3GAL5 or 
ST8SIA1 was measured. Alternatively, the correlation between 
the transcriptional activity and expression levels of ST3GAL5 
or ST8SIA1 has been suggested in a couple of studies.29,43 In 
human breast cancer cells, estradiol decreases ST8SIA1 mRNA 
expression by repression of its promoter activity through pre-
vention of NF-κB binding to the ST8SIA1 promoter.43 In our 
current study, the haplotypes of ST3GAL5 or ST8SIA1 markedly 
changed the luciferase activity of each gene (13.45−102.30%). 
Taken together with our results showing the mechanism un-
derlying the transcriptional regulation of the ST3GAL5 or 
ST8SIA1 promoter, these findings suggest that the change in 
promoter activity exhibited by ST3GAL5 or ST8SIA1 variants 
might ultimately affect the expression level and/or activity of 
ST3GAL5 or ST8SIA1.
In conclusion, we identified and characterized genetic vari-
ants in the promoter regions of ST3GAL5 and ST8SIA1 in Ko-
rean individuals. Our genotype-phenotype analysis data might 
suggest a possible link between the ST8SIA1 functional pro-
moter haplotype and the severity of TAO. To the best of our 
knowledge, this is the first study to have examined the effect 
of ST3GAL5 and ST8SIA1 promoter variants on the transcrip-
tion of genes and the relationship between haplotypes and clini-
cal phenotypes of TAO in Koreans. Further studies are war-
ranted to investigate whether these functional haplotypes of 
ST3GAL5 and ST8SIA1 promoters are associated with clinical 
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features of other diseases related to ganglioside synthesis.
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